Granules India Limited has made the audio recording of its Q4 FY26 earnings conference call available online following the successful completion of the scheduled session on April 29, 2026. The pharmaceutical company filed the update on April 29, 2026, under Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Conference Call Completion and Recording Availability

The earnings conference call was conducted as scheduled on Wednesday, April 29, 2026, at 5:00 PM IST, where the company discussed its Q4 FY26 performance and overall business developments for the financial year ended March 31, 2026. The audio recording has been uploaded to the company's official website for stakeholder access.

Management Participation

The conference call featured senior management personnel who addressed queries and provided detailed insights into the company's performance. The participating executives represented key functional areas of the organization.

Regulatory Compliance and Documentation

The notification was filed pursuant to Regulation 46 of SEBI regulations, which mandates companies to maintain and update their websites with relevant information for stakeholders. The intimation was signed by Chaitanya Tummala, Company Secretary & Compliance Officer, and digitally authenticated on April 29, 2026, at 20:03:37 +05'00'.

Granules India Limited is headquartered at 15th Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad – 500084, Telangana, India. The company maintains its investor relations through dedicated resources and provides regular updates to stakeholders through multiple communication channels.

Granules India Limited has filed its monitoring agency report for the quarter ended March 31, 2026, with the National Stock Exchange of India Limited and BSE Limited. The report, issued by M/s. India Ratings & Research Private Limited, covers the utilization of proceeds raised through the company's preferential issue in accordance with Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The preferential issue was conducted between February 10, 2026, and February 23, 2026, comprising 51,28,205 equity shares of face value ₹ 1 each at INR 585 per share and 2,50,00,000 convertible warrants at INR 585 per warrant. The total issue size amounted to INR 1,762.50 Crores. As of March 31, 2026, the company had received INR 665.63 Crores, which included the full subscription amount for equity shares (INR 300.00 Crores) and 25% upfront payment for convertible warrants (INR 365.63 Crores).

The monitoring agency confirmed no deviation from the objects of the issue based on the management undertaking and statutory auditor certificate dated April 23, 2026, issued by S.R. Batliboi & Associates LLP. The proceeds were allocated for funding business operations, including capital expenditure, operating expenses, prepayment of term loans, working capital, vendor payments, and general corporate purposes.

During the quarter ended March 31, 2026, the company utilized INR 218.14 Crores of the proceeds. The utilization included INR 44.21 Crores for salary payments under general corporate purposes and various amounts for capital expenditure, operating expenses, and investments in subsidiaries. The company also made an equity investment of INR 400.00 Crores in M/s Granules Life Sciences Private Limited during the quarter.

The unutilized proceeds of INR 447.48 Crores as of March 31, 2026, have been deployed in fixed deposits with Union Bank of India and maintained in monitoring accounts. Five fixed deposits of INR 10.00 Crores each, maturing on June 25, 2026, yielded returns at 6.80%. Additionally, INR 14.76 Crores remained in the Kotak Bank monitoring account, and INR 382.88 Crores was held with Granules Life Sciences Private Limited.

The monitoring agency noted that all projects are ongoing as per the tentative timelines specified in the offer document, with no delays reported. The company has 18 months from the issue date for warrant holders to exercise their conversion option, with the balance 75% of warrant value (INR 438.75 per warrant) to be received upon conversion.